About Innate Pharma
Innate Pharma is a company based in Marseille (France) founded in 1999 by Marc Bonneville, Jean-Jacques Fournie, and Eric Vivier. Innate Pharma has raised $43.46 million across 10 funding rounds from investors including Novo Nordisk, Sanofi and Orbimed. The company has 181 employees. Innate Pharma operates in a competitive market with competitors including Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
- Headquarter Marseille, France
- Employees 181
- Founders Marc Bonneville, Jean-Jacques Fournie, Eric Vivier
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website innate-pharma.com
- Social LinkedIn X
- Legal Name Innate Pharma Sa Class A
- Annual Revenue$3.28 M (USD)-77.92as on Dec 31, 2025
- Net Profit-$57.79 M (USD)0.59as on Dec 31, 2025
- EBITDA-$65.76 M (USD)1.99as on Dec 31, 2025
- Total Equity Funding$43.46M (USD)
in 10 rounds
- Latest Funding Round$17.07M (USD), Post-IPO
Apr 2025
- InvestorsNovo Nordisk
& 15 more
- Employee Count181
Funding Insights of Innate Pharma
Innate Pharma has successfully raised a total of $43.46M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $17.07 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $43.46M
- Total Rounds 10
- Last Round Post-IPO — $17.07M
- Investors Count 16
All 10 funding rounds of Innate Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $17.07M | Post-IPO | – | – | |
| Jun 2018 | $306,722 | Grant | – | – | – |
| Jan 2017 | $15M | Post-IPO | – | – | |
| Jun 2014 | $68.13M | Post-IPO | – | – | – |
| Nov 2013 | $27.43M | Post-IPO | – | – | |
| Jan 2010 | $35.24M | Post-IPO | – | – | – |
| Aug 2004 | $18.3M | Series C | – | – | |
| Jun 2002 | $20.97M | Series B | – | – | |
| Jun 2000 | $4.19M | Series A | – | – | |
| Jun 1999 | – | Unspecified | – | – | – |
16 investors in total: 16 institutional.
Investors in Innate Pharma
Innate Pharma has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Novo Nordisk, Sanofi and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors. | 2003 | qvt.com | - | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Private investment firm specializing in markets and partnerships. | – | ardian.com | - | |
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Smalt Capital is engaged in capital investment and renewable energy financing. | 2000 | smaltcapital.com | Marseille, France | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Venture capital investments are managed by Auriga Partners in France. | 1998 | aurigapartners.com | Paris, France | |
Online slot gaming services are offered by ng24h platform. | – | nifventures.com | - | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States |
Investor details for Innate Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Innate Pharma
58 people are tracked at Innate Pharma (23 in leadership, 14 in board & advisors, 21 in team); the tracked headcount is 181.
| Name | Role | Group |
|---|---|---|
Marc Bonneville | Co-Founder | Leadership |
Jean-Jacques Fournie | Co-Founder | Leadership |
Eric Vivier | Co-Founder | Leadership |
Marie Vetizou | R&d Director | Leadership |
Nicola Beltraminelli | VP, Chief Development Officer | Leadership |
Frederic Lombard | SVP & CFO | Leadership |
Adrien Bourbonnais | Director, Head Of CMC Pharmaceutical Operations & Supply Chain | Leadership |
Ivan Perrot | Director, Research & Drug Development | Leadership |
Melanie Douville | Director Accounting Consolidation & Treasury | Leadership |
Laurent Gauthier | Director Research & Drug Development | Leadership |
Sybille Salic | Associate Director, Internal Audit & Compliance (sox) | Leadership |
David Magrez | Director, Head Of Biostatistics & Data Management | Leadership |
Olivier Demaria | Phd, R&d Director, Science Leader | Leadership |
Dominique Manechez | Director, Clinical Development And Safety | Leadership |
Stephanie Cornen | Vice President, Investor Relations, Communication & Commercial Strategy | Leadership |
Florence Gueant | CMO & CSO Executive Assistant | Leadership |
Alexandre Walle | HRBP - C&b Senior Director | Leadership |
Irene Berkowitz | Director Legal Affairs | Leadership |
Ariane Morel | R&d Senior Director, Preclinical Research | Leadership |
Odile Laurent | VP, Human Resources & Social Relations | Leadership |
38 more people are available in the full profile.
Complete people profiles for Innate Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Innate Pharma
Innate Pharma is a publicly listed company on the EURONEXT with ticker symbol IPH in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Oct 2019
- Listed onNASDAQ: IPHA
- Listed entityInnate Pharma SA Class A
- Exchange sectorHealth technology
- ISINFR0010331421
- Share price1.30 EUR (+2.84% on the day) · 2026-10-09
- Market capitalisation145,433,848.00 EUR
- EPS (diluted, trailing year)-0.51 EUR
- Volume (last session)200,077
Financials of Innate Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.8M EUR | -49.2M EUR | -56.0M EUR |
| 2024 | 12.6M EUR | -49.5M EUR | -57.1M EUR |
| 2023 | 51.9M EUR | -7.6M EUR | -17.3M EUR |
| 2022 | 49.6M EUR | -58.1M EUR | -20.2M EUR |
| 2021 | 12.1M EUR | -52.8M EUR | -58.1M EUR |
Detailed financial statements for Innate Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Innate Pharma
4 dated milestones of Innate Pharma across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Innate Pharma is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $17.1M.
Competitors of Innate Pharma
Innate Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. |
Detailed competitors of Innate Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Innate Pharma
The website of Innate Pharma (innate-pharma.com) receives about 10.5K visits a month and ranks #2,074,647 among all websites worldwide, #2,827 in Biotechnology and Pharmaceuticals.
- Monthly visits10.5K
▼ 4.5% vs previous month
- Unique visitors4.4K
per month
- Global rank#2,074,647
among all websites
- Category rank#2,827
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.9
- Average visit47 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Innate Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ipsen.com | 100% | 112.9K | #336,868 | View details | |
| dbv-technologies.com | 92% | 18.3K | #1,234,936 | View details | |
| heidelberg-pharma.com | 84% | 3.9K | #1,811,054 | View details | |
| asteriasbiotherapeutics.com | 80% | – | – | View details | |
| biocentury.com | 77% | 85.7K | #514,907 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Innate Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Innate Pharma
Complete news archive for Innate Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Innate Pharma
10 companies that operate in the same segment as Innate Pharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Innate Pharma
Innate Pharma was founded in 1999.
Innate Pharma is headquartered in Marseille, France. It is registered at Marseille, Provence-alpes-cote D'azur, France.
Innate Pharma is a funded company, having raised a total of $43.46M across 10 funding rounds to date.
Innate Pharma has 181 employees.
Annual revenue of Innate Pharma is $3.28M as on Dec 31, 2025.
Developer of antibody-based therapeutics to treat cancer. The companys portfolio include lacutamab, developed in an advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab in non-small cell lung cancer, as well as ANKET multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma's top competitors include Merck, Moderna and Roivant Sciences.
Yes, Innate Pharma is publicly traded on EURONEXT under the ticker symbol IPH.
Innate Pharma has 16 investors. Key investors include Novo Nordisk, Sanofi, Orbimed, Gimv, and Bristol-Myers Squibb.
Innate Pharma operates through Innate Pharma, Sa.